The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Open accessAbstract
BACKGROUND: The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions. METHODS: We randomly assigned 781 patients with previously untreated CLL and a score higher than 6 on the Cumulative Illness Rating Scale (CIRS) (range, 0 to 56, with higher scores indicating worse health status) or an estimated creatinine clearance of 30 to 69 ml per minute to receive chlorambucil, obinutuzumab plus chlorambucil, or rituximab plus chlorambucil. The primary end point was investigator-assessed progression-free survival. RESULTS: The patients had a median age of 73 years, creatinine clearance of 62 ml per minute, and CIRS score of 8 at baseline. Treatment with obinutuzumab-chlorambucil or rituximab-chlorambucil, as compared with chlorambucil monotherapy, increased response rates and prolonged progression-free survival (median progression-free survival, 26.7 months with obinutuzumab-chlorambucil vs. 11.1 months with chlorambucil alone; hazard ratio for progression or death, 0.18; 95% confidence interval [CI], 0.13 to 0.24; P<0.001; and 16.3 months with rituximab-chlorambucil vs. 11.1 months with chlorambucil alone; hazard ratio, 0.44; 95% CI, 0.34 to 0.57; P<0.001). Treatment with obinutuzumab-chlorambucil, as compared with chlorambucil alone, prolonged overall survival (hazard ratio for death, 0.41; 95% CI, 0.23 to 0.74; P=0.002). Treatment with obinutuzumab-chlorambucil, as compared with rituximab-chlorambucil, resulted in prolongation of progression-free survival (hazard ratio, 0.39; 95% CI, 0.31 to 0.49; P<0.001) and higher rates of complete response (20.7% vs. 7.0%) and molecular response. Infusion-related reactions and neutropenia were more common with obinutuzumab-chlorambucil than with rituximab-chlorambucil, but the risk of infection was not increased. CONCLUSIONS: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each was combined with chlorambucil. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01010061.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Self-citationHallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationChiorazzi, N., Rai, K. R., & Ferrarini, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041720 · Cited by 1,296
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population
Parmelee, P. A., Thuras, P. D., Katz, I. R., & Lawton, M. P. (1995) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1995.tb06377.x · Cited by 948
Kröber, A., Seiler, T., Benner, A., Bullinger, L., Brückle, E., Lichter, P., Döhner, H., & Stilgenbauer, S. (2002) · Blood · doi:10.1182/blood.v100.4.1410.h81602001410_1410_1416 · Cited by 785
Self-citationTam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Self-citationFischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Self-citationAcute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Self-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Self-citationObinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Self-citationIbrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Eichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Self-citationEichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv303 · Cited by 612
Self-citationEichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.019 · Cited by 585
Self-citationNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900574 · Cited by 509
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
Self-citationon behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Kroschinsky, F., Stölzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., & Schellongowski, P. (2017) · Critical Care · doi:10.1186/s13054-017-1678-1 · Cited by 500
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25638 · Cited by 473
Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0602-x · Cited by 467
Self-citationFurie, R. A., Aroca, G., Cascino, M. D., Garg, J. P., Rovin, B. H., Alvarez, A., Fragoso-Loyo, H., Zuta-Santillan, E., Schindler, T., Brunetta, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220920 · Cited by 459
Hutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A., Salles, G., Martínez-Lopez, J., Crump, M., Thomas, D. N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03175 · Cited by 437
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
Pavlasova, G., & Mraz, M. (2020) · Haematologica · doi:10.3324/haematol.2019.243543 · Cited by 433
Vitolo, U., Trněný, M., Belada, D., Burke, J. M., Carella, A. M., Chua, N., Abrisqueta, P., Demeter, J., Flinn, I., Hong, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3402 · Cited by 417
Self-citationChanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00465-9 · Cited by 415
Self-citationFcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Styczynski, J., van der Velden, W., Fox, C. P., Engelhard, D., de la Camara, R., Cordonnier, C., Ljungman, P., & on behalf of the Sixth European Conference on Infections in Leukemia, A. J. V. O. T. I. D. W. P. O. T. E. S. O. B. A. M. T. (.-I. (2016) · Haematologica · doi:10.3324/haematol.2016.144428 · Cited by 408
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Self-citationO’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
Hallek, M., Shanafelt, T. D., & Eichhorst, B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30422-7 · Cited by 370
Self-citationAssociation of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer
Nosho, K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.557 · Cited by 344
Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., Doubek, M., Panagiotidis, P., Kimby, E., Schuh, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60027-7 · Cited by 343
Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A.-M., Robrecht, S., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30443-5 · Cited by 337
Self-citationPereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
The Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01580 · Cited by 309
Self-citationDevelopment of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., Bauer, K., Malchau, G., Rabe, K. G., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556399 · Cited by 283
Self-citationChronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 282
Self-citationABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 281
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., Boucher, R., MacDonald, D., Fegan, C., McCaig, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00894 · Cited by 272
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
DiLillo, D. J., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.04.016 · Cited by 266
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Hallek, M. (2015) · American Journal of Hematology · doi:10.1002/ajh.23979 · Cited by 263
Self-citationInhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Furie, R. A., Rovin, B. H., Garg, J. P., Santiago, M. B., Aroca-Martínez, G., Zuta Santillán, A. E., Alvarez, D., Navarro Sandoval, C., Lila, A. M., Tumlin, J. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410965 · Cited by 260
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu, J., Zhang, M., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0250-9 · Cited by 254
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
The role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028761 · Cited by 134
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“The standard conventional treatment approach in CLL is now immunochemotherapy with FCR (fludarabine, cyclophosphamide, and rituximab) for young/fit patients(109) and chlorambucil plus anti-CD20 antibodies (rituximab, obinutuzumab or ofatumumab) for elderly/unfit patients.(110) Despite the dramatic improvements in effi…”
BackgroundMhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009517 · Cited by 43
Metadata
- Authors
- Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K.-A., Stilgenbauer, S., Döhner, H., Langerak, A. W., Ritgen, M., Kneba, M., Asikanius, E., Humphrey, K., Wenger, M., & Hallek, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-03-20
- Volume
- 370
- Issue
- 12
- Pages
- 1101-1110
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120319857
- Cited by
- 1,518
- References
- 32
- FWCI
- 98.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.